| HOME >> BIOLOGY >> TECHNOLOGY |
write-off of the acquired IPR&D related to the Alantos and Ilypsa
acquisitions (see (j) above), (4) the write-off of the cost of a
semi-completed manufacturing asset (see (l) above), and (5) the tax
benefit recognized as a result of resolving certain non-routine
transfer pricing issues with the IRS (see (p) above).
(r) The following table presents the computations for GAAP and "Adjusted"
diluted earnings per share, computed under the treasury stock method.
"Adjusted" earnings per share presented below excludes stock option
expense:
Three months ended Three months ended
September 30, 2008 September 30, 2007
------------------- -------------------
GAAP "Adjusted" GAAP "Adjusted"
------------------- -------------------
Income (Numerator):
Net income for basic and
diluted EPS $1,158 $1,308 $201 $1,181
======= ======= ======= =======
Shares (Denominator):
Weighted-average shares
for basic EPS 1,058 1,058 1,086 1,086
Effect of dilutive
securities 6 5(*) 4 3(*)
------- ------- ------- -------
Weighted-average shares
for diluted EPS 1,064 1,063 1,090 1,089
======= ======= ======= =======
Diluted earnings per share $1.09 $1.23 $0.18 $1.08
======= ======= ======= =======
'/>"/>
| SOURCE Amgen Copyright©2008 PR Newswire. All rights reserved |